Gilteritinib is a second-generation FLT3 inhibitor approved by the FDA in 2018 and by the EMA in 2019 as a monotherapy for patients with relapsed/refractory FLT3 mutated AML based on the results of the phase 3 ADMIRAL trial (3). The gene discussed is FLT3; the disease is acute myeloid leukemia.